CN110799218A - 包含sting激动剂的抗体缀合物 - Google Patents

包含sting激动剂的抗体缀合物 Download PDF

Info

Publication number
CN110799218A
CN110799218A CN201880043438.4A CN201880043438A CN110799218A CN 110799218 A CN110799218 A CN 110799218A CN 201880043438 A CN201880043438 A CN 201880043438A CN 110799218 A CN110799218 A CN 110799218A
Authority
CN
China
Prior art keywords
alkyl
alkenyl
alkynyl
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880043438.4A
Other languages
English (en)
Chinese (zh)
Inventor
T·W·小杜本斯基
J·R·布鲁姆
S·坎汉
C·Y·周
K·高蒂尔
L·H·格利克曼
郝学士
D·凯恩
S·卡斯布哈特拉
G·E·卡蒂巴
T·N·L·勒
J·莱昂
J·麦肯纳
S·麦克沃特
C·O·恩杜巴库
W·欧
L·宋
G·S·特里亚
宇野哲郎
T·Y-H·吴
万咏勤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Chinook Therapeutics Inc
Original Assignee
Novartis AG
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Aduro Biotech Inc filed Critical Novartis AG
Publication of CN110799218A publication Critical patent/CN110799218A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880043438.4A 2017-04-28 2018-04-26 包含sting激动剂的抗体缀合物 Pending CN110799218A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28
US62/491,879 2017-04-28
PCT/US2018/029570 WO2018200812A1 (en) 2017-04-28 2018-04-26 Antibody conjugates comprising sting agonist

Publications (1)

Publication Number Publication Date
CN110799218A true CN110799218A (zh) 2020-02-14

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880043438.4A Pending CN110799218A (zh) 2017-04-28 2018-04-26 包含sting激动剂的抗体缀合物

Country Status (5)

Country Link
EP (1) EP3615080A1 (https=)
JP (1) JP2020517700A (https=)
CN (1) CN110799218A (https=)
AR (1) AR113224A1 (https=)
WO (1) WO2018200812A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592570A (zh) * 2020-05-15 2020-08-28 清华大学 新型sting激动剂及其制备方法和应用
CN115060902A (zh) * 2022-05-13 2022-09-16 上海市第十人民医院 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用
CN115768485A (zh) * 2020-04-02 2023-03-07 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
WO2024153127A1 (zh) * 2023-01-18 2024-07-25 泰励生物科技（上海）有限公司 抗体偶联药物及其用途
WO2025140587A1 (zh) * 2023-12-27 2025-07-03 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
CN112601555A (zh) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 与抗cd19抗体药物结合物相关的组合物和方法
BR112020024605A2 (pt) * 2018-06-01 2021-04-06 Eisai R&D Management Co., Ltd. Métodos para o tratamento de câncer de bexiga
WO2020014127A1 (en) * 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020092617A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody conjugates comprising sting agonists
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
KR20210107731A (ko) * 2018-12-21 2021-09-01 노파르티스 아게 Pmel17에 대한 항체 및 이의 접합체
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
WO2020227421A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
IL287938B2 (en) * 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
KR20220024106A (ko) 2019-05-20 2022-03-03 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
US20220267281A1 (en) * 2019-06-12 2022-08-25 Ontario Institute For Cancer Research (Oicr) Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
CA3147890A1 (en) * 2019-07-19 2021-01-28 Immunesensor Therapeutics, Inc. Antibody-sting agonist conjugates and their use in immunotherapy
JP7843695B2 (ja) 2019-08-02 2026-04-10 メルサナ セラピューティクス インコーポレイテッド がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
CN115003383B (zh) * 2019-08-21 2024-10-01 斯克里普斯研究学院 干扰素基因刺激物sting的双环激动剂
KR20210028544A (ko) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
EP4088739A4 (en) * 2019-12-23 2024-11-13 Eisai R&D Management Co., Ltd. PROCESS FOR PRODUCING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN
IL296124A (en) * 2020-03-06 2022-11-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative
BR112022019532A2 (pt) * 2020-03-31 2022-12-06 Orum Therapeutics Inc Conjugados de neodegrader
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
MX2022014110A (es) 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514707A (ja) 2021-04-20 2024-04-02 アンスティテュ・クリー 免疫療法における使用のための組成物及び方法
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
CA3222082A1 (en) * 2021-06-25 2022-12-29 Gary Brandt Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
JP2024526874A (ja) 2021-07-23 2024-07-19 イミューンセンサー セラピューティクス、インコーポレイテッド サイトカインとのｓｔｉｎｇアゴニスト併用療法
CN118524854A (zh) * 2021-12-17 2024-08-20 北京加科思新药研发有限公司 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途
CN120239705A (zh) 2022-07-21 2025-07-01 萤火虫生物股份有限公司 糖皮质激素受体激动剂和其缀合物
TW202432101A (zh) * 2022-11-08 2024-08-16 韓商瑞嘉化學生物科學股份有限公司 Sting促效劑
AU2024234194A1 (en) 2023-03-10 2025-08-07 Novartis Ag Panras inhibitor antibody-drug conjugates and methods of use thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy
AR133955A1 (es) 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2025233676A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and immune checkpoint inhibitors
WO2025233679A1 (en) * 2024-05-08 2025-11-13 Ligachem Biosciences Inc. Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145102A1 (en) * 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
ES2732574T3 (es) 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
EP3317290A4 (en) 2015-07-02 2019-04-10 Spring Bank Pharmaceuticals, Inc. COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
CN106540256A (zh) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109715202A (zh) 2016-07-15 2019-05-03 斯必乐维生物科学公司 用于治疗疾病的化合物、组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145102A1 (en) * 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2017100305A2 (en) * 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAURENT DUCRY等: "Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies" *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115768485A (zh) * 2020-04-02 2023-03-07 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
CN111592570A (zh) * 2020-05-15 2020-08-28 清华大学 新型sting激动剂及其制备方法和应用
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
CN115060902A (zh) * 2022-05-13 2022-09-16 上海市第十人民医院 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用
CN115060902B (zh) * 2022-05-13 2025-07-11 上海市第十人民医院 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用
WO2024153127A1 (zh) * 2023-01-18 2024-07-25 泰励生物科技（上海）有限公司 抗体偶联药物及其用途
WO2025140587A1 (zh) * 2023-12-27 2025-07-03 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用

Also Published As

Publication number Publication date
WO2018200812A1 (en) 2018-11-01
AR113224A1 (es) 2020-02-19
EP3615080A1 (en) 2020-03-04
JP2020517700A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
CN110799218A (zh) 包含sting激动剂的抗体缀合物
US20210346387A1 (en) Antibody conjugates comprising toll-like receptor agonist
US20200164084A1 (en) Antibody conjugates comprising toll-like receptor agonist and combination therapies
US20210170043A1 (en) Dc-sign antibody conjugates comprising sting agonists
US20230053449A1 (en) Dc-sign antibody drug conjugates
WO2020089815A1 (en) Antibody conjugates comprising sting agonist
EP4135775A1 (en) Diels-alder conjugation methods
RU2847195C1 (ru) Способы конъюгации дильса-альдера
HK1257776B (en) Antibody conjugates comprising toll-like receptor agonist

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Basel, Switzerland

Applicant after: NOVARTIS AG

Applicant after: Chinook medical Co.

Address before: Basel, Switzerland

Applicant before: NOVARTIS AG

Applicant before: ADURO BIOTECH, Inc.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200214

WD01 Invention patent application deemed withdrawn after publication